Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Oxford Lane Capital Corp is an asset management business based in the US. Oxford Lane Capital shares (OXLC) are listed on the NASDAQ and all prices are listed in US Dollars.
|Latest market close||$7.76|
|52-week range||$3.72 - $7.90|
|50-day moving average||$7.37|
|200-day moving average||$7.19|
|Wall St. target price||$8.00|
|Dividend yield||$1.012 (12.94%)|
|Earnings per share (TTM)||$2.89|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||1.44%|
|1 month (2021-09-24)||9.45%|
|3 months (2021-07-23)||6.16%|
|6 months (2021-04-23)||17.40%|
|1 year (2020-10-23)||75.17%|
|2 years (2019-10-24)||-19.08%|
|3 years (2018-10-24)||10.15|
|5 years (2016-10-24)||10.25|
Valuing Oxford Lane Capital stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Oxford Lane Capital's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Oxford Lane Capital's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Oxford Lane Capital shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||$127.3 million|
|Operating margin TTM||72.79%|
|Gross profit TTM||$127.3 million|
|Return on assets TTM||7.9%|
|Return on equity TTM||67.03%|
|Market capitalisation||$906.5 million|
TTM: trailing 12 months
There are currently 507,889 Oxford Lane Capital shares held short by investors – that's known as Oxford Lane Capital's "short interest". This figure is 11.5% down from 573,776 last month.
There are a few different ways that this level of interest in shorting Oxford Lane Capital shares can be evaluated.
Oxford Lane Capital's "short interest ratio" (SIR) is the quantity of Oxford Lane Capital shares currently shorted divided by the average quantity of Oxford Lane Capital shares traded daily (recently around 940535.18518519). Oxford Lane Capital's SIR currently stands at 0.54. In other words for every 100,000 Oxford Lane Capital shares traded daily on the market, roughly 540 shares are currently held short.
However Oxford Lane Capital's short interest can also be evaluated against the total number of Oxford Lane Capital shares, or, against the total number of tradable Oxford Lane Capital shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oxford Lane Capital's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Oxford Lane Capital shares in existence, roughly 0 shares are currently held short) or 0.0044% of the tradable shares (for every 100,000 tradable Oxford Lane Capital shares, roughly 4 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Oxford Lane Capital.
Find out more about how you can short Oxford Lane Capital stock.
Dividend payout ratio: 12.44% of net profits
Recently Oxford Lane Capital has paid out, on average, around 12.44% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 10.44% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Oxford Lane Capital shareholders could enjoy a 10.44% return on their shares, in the form of dividend payments. In Oxford Lane Capital's case, that would currently equate to about $1.012 per share.
While Oxford Lane Capital's payout ratio might seem low, this can signify that Oxford Lane Capital is investing more in its future growth.
Oxford Lane Capital's most recent dividend payout was on 28 March 2019. The latest dividend was paid out to all shareholders who bought their shares by 14 November 2021 (the "ex-dividend date").
Over the last 12 months, Oxford Lane Capital's shares have ranged in value from as little as $3.7193 up to $7.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oxford Lane Capital's is 1.1259. This would suggest that Oxford Lane Capital's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Oxford Lane Capital Corp. is a close ended fund launched and managed by Oxford Lane Management LLC. It invests in fixed income securities. The fund primarily invests in securitization vehicles which in turn invest in senior secured loans made to companies whose debt is rated below investment grade or is unrated. Oxford Lane Capital Corp was formed on June 9, 2010 and is domiciled in the United States. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.